Cargando…

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma

INTRODUCTION: Metastatic pancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis and significant morbidity from local tumor progression. We investigated outcomes among oligometastatic PDAC patients treated with stereotactic magnetic resonance image-guided ablative radiotherapy (SMART) to pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webking, Samantha, Sandoval, Maria L., Chuong, Michael D., Ucar, Antonio, Aparo, Santiago, De Zarraga, Fernando, Sahin, Ibrahim, Biachi, Tiago, Kim, Dae W., Hoffe, Sarah E., Frakes, Jessica M., Palm, Russell F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693219/ https://www.ncbi.nlm.nih.gov/pubmed/38038261 http://dx.doi.org/10.1177/10732748231219069

Ejemplares similares

Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
por: Bryant, JM, et al.
Publicado: (2023)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
por: Finkelstein, Steven Eric, et al.
Publicado: (2011)

Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy
por: Chuong, Michael D., et al.
Publicado: (2022)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
por: Al-Shafa, Faiez, et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care
por: Raymakers, Adam J. N., et al.
Publicado: (2021)

Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART)
por: Bryant, J.M., et al.
Publicado: (2022)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer
por: Chuong, Michael D., et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Venkat, Puja S., et al.
Publicado: (2017)

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy
por: O'Cathail, Sean M., et al.
Publicado: (2020)

Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer
por: Wijetunga, N. Ari, et al.
Publicado: (2021)

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients
por: Ma, Ming-Wei, et al.
Publicado: (2022)

Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04)
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Vertebral compression fracture after stereotactic ablative radiotherapy in patients with oligometastatic bone lesions from hepatocellular carcinoma
por: Hyung Kim, Tae, et al.
Publicado: (2023)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma
por: Burgess, Laura, et al.
Publicado: (2021)

Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States
por: Sheth, Niki, et al.
Publicado: (2020)

The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
por: Dahele, Max, et al.
Publicado: (2011)

Peripheral blood lymphocyte changes after stereotactic ablative body radiotherapy to lung or liver metastases in patients with oligometastatic cancers
por: Novikov, Sergey Nikolaevich, et al.
Publicado: (2023)

Case report: L5 tomita En bloc spondylectomy for oligometastatic liposarcoma with post adjuvant stereotactic ablative radiotherapy
por: Saha, Priyanshu, et al.
Publicado: (2023)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments
por: Navarria, Pierina, et al.
Publicado: (2014)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gkv5vb1kqa9f0jiou6ma41j4p9